In April of this year, Takeda Pharmaceutical, Japan’s largest drug company purchased Millennium Pharmaceuticals, one of the earliest American genomics companies for nearly $9 billion providing Takeda an entry into the cancer-drug market. During this off-the-record discussion, topics will include:
- Important criteria each company sought in a strategic partner
- Communicating effectively through cultural differences
- Lessons learned during the due diligence process
- Approach for successful integration of the two companies
Presenters included:
- Gabor Garai, Co-Chair, Life Sciences Industry Team, Foley
- Dr. Daniel Curran, Vice President, Corporate Development, Millennium Pharmaceuticals Inc.
- Catherine Sazdanoff, Vice President, Global Licensing, Takeda Pharmaceuticals North America, Inc.
Related Insights
June 20, 2025
Foley Career Perspectives
Foley Juneteenth Program: Exploring the Hidden History to Further Our Mutual Understanding
In celebration of Juneteenth, Foley & Lardner welcomed Dr. Deirdre Cooper Owens, author and historian, for a firmwide virtual program on…
July 10, 2025
Events
Mandatory Roth Catch-up
Join Foley’s upcoming webinar on mandatory Roth catch-up contributions effective January 1, 2026. Learn how the new rules impact high earners, what guidance exists, and practical tips for plan compliance.
June 20, 2025
Foley Viewpoints
Federal Court Enjoins Former Franchisees and Two Related Entities from Competing Against Franchisor
A federal court recently granted in part and denied in part a franchisor’s motion to enjoin the post-termination activities of its former…